全文获取类型
收费全文 | 88538篇 |
免费 | 6524篇 |
国内免费 | 3768篇 |
专业分类
耳鼻咽喉 | 857篇 |
儿科学 | 2424篇 |
妇产科学 | 950篇 |
基础医学 | 16530篇 |
口腔科学 | 790篇 |
临床医学 | 6315篇 |
内科学 | 23123篇 |
皮肤病学 | 1627篇 |
神经病学 | 4437篇 |
特种医学 | 2249篇 |
外国民族医学 | 8篇 |
外科学 | 6025篇 |
综合类 | 11999篇 |
现状与发展 | 14篇 |
预防医学 | 8858篇 |
眼科学 | 1099篇 |
药学 | 5683篇 |
21篇 | |
中国医学 | 2436篇 |
肿瘤学 | 3385篇 |
出版年
2024年 | 38篇 |
2023年 | 851篇 |
2022年 | 1291篇 |
2021年 | 2659篇 |
2020年 | 2458篇 |
2019年 | 2490篇 |
2018年 | 2549篇 |
2017年 | 2541篇 |
2016年 | 2906篇 |
2015年 | 3270篇 |
2014年 | 4662篇 |
2013年 | 5215篇 |
2012年 | 4637篇 |
2011年 | 5371篇 |
2010年 | 4483篇 |
2009年 | 4131篇 |
2008年 | 4208篇 |
2007年 | 4359篇 |
2006年 | 4000篇 |
2005年 | 3434篇 |
2004年 | 3106篇 |
2003年 | 2907篇 |
2002年 | 3260篇 |
2001年 | 3493篇 |
2000年 | 3361篇 |
1999年 | 2465篇 |
1998年 | 2198篇 |
1997年 | 2027篇 |
1996年 | 1435篇 |
1995年 | 1304篇 |
1994年 | 1083篇 |
1993年 | 868篇 |
1992年 | 705篇 |
1991年 | 624篇 |
1990年 | 501篇 |
1989年 | 483篇 |
1988年 | 441篇 |
1987年 | 342篇 |
1986年 | 314篇 |
1985年 | 525篇 |
1984年 | 386篇 |
1983年 | 282篇 |
1982年 | 268篇 |
1981年 | 236篇 |
1980年 | 183篇 |
1979年 | 138篇 |
1978年 | 123篇 |
1977年 | 73篇 |
1976年 | 58篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
[摘要] 目的 分析新型冠状病毒肺炎疫情(新冠疫情)暴发前、后2个年度,安庆市流行性感冒(流感)流行的强度和特征。方法 在“中国流感监测信息系统”中选取安庆市2019—2021年度监测数据,分析我市新冠疫情发生前、后的流感样病例就诊百分比、病原学阳性率和聚集性疫情的变化。结果 新冠疫情前、后2个年度,流感样病例就诊百分比分别为4.17%和3.78%,差异有统计学意义(χ2=56.652,P=0.000);病原学阳性率分别为23.43%和1.15%,差异有统计学意义(χ2=538.694,P=0.000)。新冠疫情前的流感病毒活动呈现双峰分布,新冠疫情后全年仅检出27份流感病毒阳性样本。结论 新冠疫情中采取的严格非药物预防措施,对流感的季节性特征有重要影响。应通过疫苗接种和非药物预防等措施,做好流感防控工作。 相似文献
2.
[摘要] 目的 分析新型冠状病毒肺炎疫情(新冠疫情)暴发前、后2个年度,安庆市流行性感冒(流感)流行的强度和特征。方法 在“中国流感监测信息系统”中选取安庆市2019—2021年度监测数据,分析我市新冠疫情发生前、后的流感样病例就诊百分比、病原学阳性率和聚集性疫情的变化。结果 新冠疫情前、后2个年度,流感样病例就诊百分比分别为4.17%和3.78%,差异有统计学意义(χ2=56.652,P=0.000);病原学阳性率分别为23.43%和1.15%,差异有统计学意义(χ2=538.694,P=0.000)。新冠疫情前的流感病毒活动呈现双峰分布,新冠疫情后全年仅检出27份流感病毒阳性样本。结论 新冠疫情中采取的严格非药物预防措施,对流感的季节性特征有重要影响。应通过疫苗接种和非药物预防等措施,做好流感防控工作。 相似文献
3.
Wan-Jun Zhang Li-Qiang Wu Jun Wang Sheng-Yun Lin Bo Wang 《World Journal of Clinical Cases》2022,10(23):8242-8248
ABSTRACT
BACKGROUND
Hepatitis-associated aplastic anemia (HAAA) is a rare condition. Patients with HAAA usually present with acute hepatitis, jaundice and significantly increased transaminase. After 1–2 mo, hepatitis gradually improves, but progressive hemocytopenia, bone marrow hematopoietic failure, and severe or extremely severe aplastic anemia are manifest. Most cases of HAAA are fulminant and usually lethal if left untreated. The literature on Epstein–Barr virus (EBV)-associated HAAA is sparse.
CASE SUMMARY
We report a 30-year-old man who was admitted to our hospital because of pale yellow urine and skin with a simultaneous decrease in peripheral blood ternary cells. We made a diagnosis of EBV-associated HAAA. The treatment strategy for this patient included eltrombopag, an immunosuppressive regimen of rabbit anti-human thymocyte immunoglobulin, cyclosporine, and supportive care. The patient was discharged in normal physical condition after five months. A hemogram performed on follow-up revealed that he had achieved a complete response.
CONCLUSION
Eltrombopag plus anti-thymocyte globubin and cyclosporine may be a therapeutic option for EBV-associated HAAA.Larger studies are warranted to confirm. 相似文献
4.
[摘要]?目的?结合环介导等温扩增技术(loop-mediated isothermal amplification, LAMP)和微流控芯片技术,建立一种适合现场快速检测登革病毒的方法。方法?利用RT-LAMP,针对登革病毒基因组中3’非编码区中特异性序列进行扩增,建立基于微流控芯片技术的LAMP检测方法,优化检测体系,并对该方法的灵敏性和特异性进行评估。结果?基于LAMP 和微流控芯片技术的登革病毒检测方法,通过对病毒模板进行扩增,发现与其他病毒无交叉反应,特异性良好;同时,结果显示该方法对登革病毒检测灵敏性可达61.2 pg/μl,与实时荧光定量PCR仪所达到的检测灵敏性一致。结论?基于LAMP和微流控芯片技术的登革病毒检测方法具有操作简单、快速、对设备要求低等优势,并且灵敏性、特异性均较好,是一种便于开展现场快速检测的方法。 相似文献
5.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
6.
7.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献
8.
9.
10.
《Transfusion and apheresis science》2022,61(4):103418
AimTo determine whether convalescent angiotensin (1?7) peptide replacement therapy with plasma (peptide plasma) transfusion can be beneficial in the treatment of critically ill patients with severe coronavirus 2 (SARS-CoV-2) infection.Study designCase series of 9 critically ill patients with laboratory-confirmed COVID-19 who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment.Peptide plasma: Plasma with angiotensin (1?7) content 8–10 times higher than healthy plasma donors was obtained from suitable donors. Peptide plasma transfusion was applied to 9 patients whose clinical status and/or laboratory profile deteriorated and who needed intensive care for 2 days.ResultsIn our COVID-19 cases, favipiravir, low molecular weight heparin treatment, which is included in the treatment protocol of the ministry of health, was started. Nine patients with oxygen saturation of 93% and below despite nasal oxygen support, whose clinical and/or laboratory deteriorated, were identified. The youngest of the cases was 36 years old, and the oldest patient was 85 years old. 6 of the 9 cases had male gender. 3 cases had been smoking for more than 10 years. 4 cases had at least one chronic disease.In all of our cases, SARS CoV2 lung involvement was bilateral and peptide plasma therapy was administered in cases when oxygen saturation was 93% and below despite nasal oxygen support of 5 liters/minute and above, and intensive care was required. Although it was not reflected in the laboratory parameters in the early period, 8 patients whose saturations improved with treatment were discharged without the need for intensive care. However, a similar response was not obtained in one case. Oxygen requirement increased gradually and, he died in intensive care process. An increase of the platelet count was observed in all cases following the peptide plasma treatment.ConclusionIn this preliminary case series of 9 critically ill patients with COVID-19, administration of plasma containing angiotensin (1?7) was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials. 相似文献